At the Outsourcing in Clinical Trials East Coast 2025 conference in King of Prussia, panelists were asked how trial sponsors ...

Ionis Pharmaceuticals has reported outcomes from the Phase III Essence study of olezarsen in individuals with moderate ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial of ifinatamab ...

The progress the UK has made as a global contributor to clinical trials is “remarkable”, says former health minister Lord ...

The theme for International Clinical Trials Day 2025, set by the Association of Clinical Research Professionals is “Powered by Purpose”.

Sarepta Therapeutics has announced new outcomes from its Phase Ib Study 9001-103, named Endeavour, of Elevidys for DMD.

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.

IQVIA has partnered with SCRI Development Innovations, the contract research organisation side of the Sarah Cannon Research ...

East Coast conference is set to take place on May 20–21, 2025, at the Valley Forge Casino Resort in King of Prussia, ...